Biopharma contributes to key global health discussions at WHA69
Find out here our take on the 69th World Health Assembly (WHA69) with some key relevant links included!
Read More
Pharmacovigilance of biotherapeutic medicines
A new study released in June 2016 identifying global case studies illustrating successes and challenges. A must read!
Read More
Our response to Zika virus
Check here about the R&D blueprint against Zika
Read More
Women’s Cancer Initiative in the Americas
Partnership to improve prevention of women’s cancers and quality of cancer registries in LAC reaches 1 year milestone
Read More
Latest News
2018-12-10 13:14:17
Unjela Kaleem joins global pharma association as Director of Communications
Geneva, 10 December 2018 – IFPMA, the global research-based biopharmaceutical industry association, is pleased to announce Ms Unjela Kaleem as ...
Read More2018-12-05 12:00:49
R&D biopharmaceutical industry revamp ethical code to apply as base line of industry behavior worldwide
New R&D biopharmaceutical industry Code of Practice comes into effect on 1 January 2019. Changes ...
Read More2018-12-04 17:17:22
David A. Ricks Elected New President of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly and Company, takes over as ...
Read More2018-11-16 06:30:08
Pharma industry launches call for coalition of countries to pilot new incentives for antibiotic R&D
16 November, Geneva – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) draws attention ...
Read More2018-11-13 09:35:59
The largest private sector coalition to provide sustainable solutions to curb antimicrobial resistance (AMR) has made strides in 2018 and calls for a coordinated and multi-pronged response from all stakeholders
The AMR Industry Alliance has made major strides in 2018 taking action across four different ...
Read More2018-10-29 10:25:29
The R&D biopharmaceutical industry supports the Astana Declaration and renewed political commitment towards the importance of primary health care
26 October 2018, Astana – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the ...
Read More2018-09-27 17:57:02
The R&D-based biopharmaceutical industry welcomes the UN Declaration on NCDs and calls for innovative financing models and multi-sectoral collaboration
New York, 27 September 2018 – As an official UN interlocutor that shares knowledge and ...
Read More
Latest Statement
2018-10-12 14:58:26
R&D biopharmaceutical industry at WHS 2018 urges finding joint solutions to achieve better health outcomes including forging impactful partnerships
Sunday, 14 October 2018, Berlin – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the body accredited by the ...
Read More2018-10-04 16:50:33
Global Business Coalition - Knowledge Partners of Global Health & Human Resources Knowledge Partnership Issue Statement
New York, 27 September 2018 – As an official UN ...
Read More2018-09-27 17:58:18
R&D-based biopharmaceutical industry welcomes UN Declaration on NCDs
New York, 27 September 2018 – As an official UN ...
Read More2018-09-26 22:55:57
R&D-based biopharmaceutical industry welcomes UN Declaration on TB
New York, 27 September 2018 – As an official UN ...
Read More2018-09-20 10:31:00
68th WHO Regional Committee for Europe: Roadmap for access 2019–2023: Comprehensive support for access to medicines and vaccines
New York, 27 September 2018 – As an official UN ...
Read More2018-08-30 14:17:00
WHO Afro 68 agenda item 12: Status of implementation of the four time-bound commitments on noncommunicable diseases in the Africa region
New York, 27 September 2018 – As an official UN ...
Read More2018-08-30 14:16:42
WHO Afro 68 agenda item 14: Roadmap for access 2019–2023: Comprehensive support for access to medicines and vaccines
New York, 27 September 2018 – As an official UN ...
Read More
mailto:s.kaenzig@ifpma.org +41 22 338 32 49
direct line
Twitter skaenzig
Sadia Kaenzig - Communications Manager
Sadia manages communications on issues including regulatory, intellectual property protection, trade and the economic footprint of the research-based pharmaceutical industry, research and development ecosystem and innovation, vaccines including influenza vaccines, and biotherapeutics.
mailto:m.depol@ifpma.org +41 22 338 32 20
direct line
Twitter @MorganePol
Morgane De Pol - Communications and Public Affairs
Morgane manages communications on issues including the research-based pharmaceutical industry’s commitment to achieving sustainable and inclusive development, advancing Universal Health Coverage, designing transformational partnerships to build healthier societies, boosting innovation for neglected tropical diseases, expanding access to high quality treatments for infectious and chronic diseases, fighting counterfeit medicines, and promoting resilient and efficient health systems.
Our Brouchure
2015 Edition
A shared commitment to global health
At IFPMA we advocate policies and practices that encourage the discovery of and access to life-saving and life-enhancing medicines and vaccines, for people everywhere.
Our Logo
Full colour EPS format
Our Logo
Full colour PNG format
FULL Name LOGO
Full colour EPS format
FULL Name LOGO
Full colour PNG format
Hot Topic
Pharmacovigilance: Do your bit, play your part!
Pharmacovigilance is one of the key steps to ensuring the safety of all our medicines, including biotherapeutics and vaccines. It encourages an ongoing cycle of communication between patients, health professionals, regulatory authorities, and our biopharma industry which is
Read MoreInterview
IFPMA 2015 interview series 'Biodiversity, human health, and pharma'
A must-watch: Dr Manisha A. Desai, assistant general patent counsel at Eli Lilly and Company, gives her take on the importance of the Convention of Biodiversity and the Nagoya Protocol for the pharma industry. What's key is to
Read MoreOur Blog
Cultivating Trust in Healthcare System
This oped was first published in The Pharma Letter on 6 December 2018. Business performance is mostly about the tangible: robust pipeline, successful launches, development of sales, financial results, profit margins, and the like. One less tangible but absolutely crucial measure of success relates to “how” we go about our business. Ethics and building trust matter just as much as the number of medicines that...
Read More
By 2050, superbugs may cost the economy $100 trillion
This oped was first published in the Antimicrobial Resistance campaign in the Guardian on 12 November 2018 Antimicrobial resistance (AMR) is on course to overtake cancer and account for 10m deaths a year by 2050. Already, 700,000 people die from drug-resistant infections (“superbugs”) each year. AMR could cost the global economy up $100 trillion – and push 28m more people into poverty. The life-science...
Read More
La réponse au virus Ebola, enjeu de sécurité sanitaire mondiale
This oped was first published on AGEGI on 25 October 2018. Résumé : Avec Ebola chaque pays est vulnérable face aux épidémies et la solution passe par une couverture universelle de santé et un travail collectif Même si l’Organisation Mondiale de la Santé (OMS) a récemment décidé qu’il n’y a pas lieu de déclarer une épidémie du virus Ebola en République démocratique u Congo (RDC), les...
Read MoreLatest Tweets
@IFPMA @IFPMA @IFPMA @IFPMA @IFPMA 